Category Archives: News

FDA approves new treatment for certain digestive tract cancers

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This is the first time a radioactive … Continue reading

Posted in News | Leave a comment

IBA Molecular Acquisition

Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million. PR Newswire Mallinckrodt NEWSROO

Posted in News | Leave a comment

Lymphoseek Tc-99

Lymphoseek is approved in the U.S. and in teh European Union (EU) for use in lymphatic mapping to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative … Continue reading

Posted in News | Leave a comment

Gallium-68 DOTATATE as an orphan drug

Gallium-68 DOTATATE has received orphan drug designation status, granted by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use of Gallium-68 DOTATATE as a diagnostic agent for the management of Gastro-Entero-Pancreatic Neuroendocrine Tumors … Continue reading

Posted in News | Leave a comment

A freeware portable database of adverse reactions and drug interactions with radiopharmaceuticals

A paper has just been published in the Journal of Nuclear Medicine Technology  about a freeware database compiling drug interaction and adverse event data for use by nuclear medicine clinicians. The software has been developed by two Spanish radiopharmacy specialists: Ana Agudo … Continue reading

Posted in News | Leave a comment

A new option for radioimmunotherapy in lymphoma patients

A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical. According to data from the study “Radioimmunotherapy … Continue reading

Posted in News | Leave a comment

Xofigo (Alpharadin)

Xofigo (radium Ra 223 dichloride), formerly known as Alpharadin, has been approved by the US FDA for symptomatic late-stage (metastatic) castration-resistant prostate cancer that has reached bones but not other organs, i.e. with no known visceral metastatic disease. According to … Continue reading

Posted in News | Leave a comment